Tissue Cell. 2026 Nov 10;105:104136. doi: 10.1016/j.tice.2026.104136. Online ahead of print.
ABSTRACT
Platinum resistance remains the major obstacle in ovarian cancer treatment, yet the role of lipid metabolism regulators in chemo-resistance mechanisms is not well understood. To address this, this study combined computational and experimental approaches to identify FABP4 as a candidate factor associated with platinum resistance through ferroptosis suppression. Transcriptomic data from GSE51373 were analyzed using limma for differential expression, and machine learning algorithms (XGBoost/Lasso/Random Forest) were employed to prioritize resistance-associated genes. Platinum-resistant ovarian cancer cell lines (Resistance Index,RI=3.8) were established by pulse exposure to increasing cisplatin concentrations (0.5-10 μM) over 6 months for functional validation. In vitro assays, including CCK-8 proliferation,Annexin V/PI apoptosis detection, ROS detection, ferroptosis markers (GPX4 activity/MDA/Western blot), and shRNA-mediated FABP4 knockdown, were performed, and the therapeutic potential was evaluated in BALB/c nude mouse xenografts. The results showed that multi-algorithm screening identified FABP4 as a top platinum resistance biomarker (AUC=0.861,95% CI: 0.782-0.940). TCGA survival analysis further revealed that high FABP4 expression was significantly associated with worse prognosis in ovarian cancer. Experimentally, FABP4 was upregulated in resistant cells (p < 0.01), and its knockdown suppressed proliferation (p < 0.01) and tumor growth (p < 0.001). Mechanistically, FABP4 was associated with reduced intracellular ROS and alterations in ferroptosis markers, as demonstrated by increased GPX4 activity and SLC7A11 expression and decreased lipid peroxidation (MDA reduced 35%, p < 0.01) in resistant cells. Notably, FABP4 knockdown increased cisplatin-induced apoptosis and elevated ROS levels. In conclusion, FABP4 is associated with platinum resistance and correlates with ROS-dependent ferroptosis marker alterations, and may restore chemosensitivity, offering a potential therapeutic strategy for refractory ovarian cancer.
PMID:43033555 | DOI:10.1016/j.tice.2026.104136